Rick Maffei

November/December 2020 Digital Issue Click here to flip through this digital issue.

[Cancer Management and Research] Retrospective review sought to determine how residual tumor diameter and number of cycles of adjuvant chemotherapy after surgery influenced prognosis for patients with OCCC.

[Journal of Hepatocellular Carcinoma] Researchers at UT MD Anderson Cancer Center assessed the value of chest, abdominal, and pelvic CT in the surveillance of patients with HCC, and the potential drawbacks to the practice.

[Breast Cancer: Targets and Therapy] This review focuses on alpelisib, a PI3K inhibitor, approved for the treatment of HR+/HER2 negative metastatic breast cancer in patients with a PIK3CA mutation who have received prior endocrine therapy.

The following article features coverage from the ASH 2020 virtual meeting. Click here to read more of Oncology Nurse Advisor‘s conference coverage.  

News coverage from the ASH 2020 virtual meeting.

[Breast Cancer: Targets and Therapy] This review focuses on understanding how breast cancer responds to treatment and how resistance develops.

Oncology Nursing Society released evidence-based guidelines for managing radiodermatitis in patients with cancer undergoing radiotherapy.

[OncoTargets and Therapy] Investigators from the Mayo Clinic in Jacksonville, Florida, review treatment strategies for mCRPC using CDK4/6 inhibitors and combination therapies.

[Breast Cancer: Targets and Therapy] This review summarizes current knowledge of predictors and prognostic biomarkers of this rare and highly aggressive subtype of breast cancer.